# NovaVision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novavision

- Industry: Medical Devices & Equipment
- Headquarters: Boca Raton, US
- Website: www.novavision.com
- Total disclosed funding: $38M
- Latest round: Series C (Dec 27, 2006)
- Investors on record: 6

## About

NovaVision, Inc. is dedicated to providing innovative vision restoration therapies for stroke and traumatic brain injury patients, focusing on enhancing visual functions through advanced therapeutic products.Founded in 1998 in Boca Raton, US, NovaVision, Inc. specializes in vision restoration therapy. The company has completed 5 deals, with the most recent being a TRADE SALE in August 2022, where it raised USD 0.90 mn from Vycor Medical, Inc. The founder's previous ventures are not detailed, and there are no mentions of subsidiaries or parent companies.NovaVision specializes in vision restoration therapy targeted at stroke and traumatic brain injury (TBI) patients, offering two primary product lines: Vision Restoration Therapy (VRT) and NeuroEyeCoach. VRT is an FDA-cleared treatment designed to stimulate impaired visual functions through repetitive light stimulation, aiming to improve the sensitivity of a patient's field of vision and enhance residual vision in areas of partial injury. NeuroEyeCoach complements this by training patients to effectively scan their surroundings and utilize remaining visual fields, integrating left and right vision. These products are designed for both individual patients and medical professionals, serving a broad client base that includes stroke survivors and rehabilitation facilities across the United States, with a focus on addressing the substantial gap in post-stroke vision rehabilitation therapies. The therapies are delivered via an internet-based platform, enabling patients to engage in treatment from home, thus increasing accessibility and convenience.NovaVision's revenue model revolves around the provision of therapeutic services via its flagship offerings, VRT and NeuroEyeCoach. The company operates on a direct-to-consumer basis, allowing patients to access these therapies through subscriptions or one-time purchases via an online platform. Payment structures may include monthly subscriptions for at-home therapy programs or fees for individual therapy sessions, tailored to meet the needs of stroke and TBI patients. The integration of both VRT and NeuroEyeCoach into a comprehensive therapy suite provides a unique value proposition in the market, catering to both patient needs and physician referrals. The therapeutic services are aimed at enhancing the quality of life for patients experiencing vision loss, capitalizing on the growing awareness and need for specialized neurological rehabilitation solutions.In August 2022, Incline Equity Partners invested in NovaVision, Inc., with the investment expected to strengthen the company's capabilities while supporting its next phase of growth. The company is focusing on launching new products designed to enhance vision restoration therapies and plans to expand its services into additional markets, particularly targeting regions with high incidences of stroke and TBI. Specific timelines for these initiatives have not been disclosed.

## Funding rounds

- Series C, Dec 27, 2006, $20M — Noro-Moseley Partners, Tullis Health Investors, Chicago Growth Partners, Johnson & Johnson Innovation, Oakwood Medical Investors
- Series B, Feb 1, 2005, $12M — Noro-Moseley Partners, Tullis Health Investors, Crossbow Ventures
- Series A, Sep 29, 2003, $6M — Noro-Moseley Partners, Crossbow Ventures

## Investors

- Noro-Moseley Partners (https://capitalatlas.ai/funds/noro-moseley-partners) — Series A, Series B, Series C
- Crossbow Ventures (https://capitalatlas.ai/funds/crossbow-ventures) — Series A, Series B
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series B, Series C
- Chicago Growth Partners (https://capitalatlas.ai/funds/chicago-growth-partners) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series C